Study findings from University of Leicester provide new insights into solid cancer
2009 JUL 14 - (NewsRx.com) -- According to a study from Leicester, the United Kingdom, "The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI((TM))) with activity against cell-cycle progression and angiogenesis, was investigated in patients by administration for 14 consecutive days followed by 14 days recovery. with solid tumours resistant to standard treatments were enrolled in an accelerated titration design." "Thirty-seven patients received ZK 304709 from 15 to 285 mg daily. The most common drug-related adverse events were vomiting, diarrhoea and fatigue. Systemic exposure to ZK 304709 increased with dose up to 90 mg daily but plateaued thereafter, with high inter-individual variability at all doses. Thirteen patients had stable disease as best response as per RECIST criteria. There was no increase in exposure to ZK 304709 with dose escalation above 90 mg, and the MTD was not determined," wrote E.N. Scott and colleagues, University of Leicester. The researchers concluded: "This study illustrates the importance of phase I pharmacokinetic data to guide dose escalation and drug development." Scott and colleagues published their study in Cancer Chemotherapy and Pharmacology (A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI((TM))), in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2009;64(2):425-429). For more information, contact A.L. Thomas, University of Leicester, Leicester Royal Infirmary, Dept. of Oncology, Leicester LE1 5WW, Leics, UK. Publisher contact information for the journal Cancer Chemotherapy and Pharmacology is: Springer, 233 Spring St., New York, NY 10013, USA. Keywords: United Kingdom, Leicester, Angiogenesis, Chemotherapy, Clinical Trial Research, Drug Development, Drug Resistance, Drug Therapy, Drugs, Enzyme Research, Kinase, Oncology, Pharmaceuticals, Pharmacokinetics, Pharmacology, Solid Cancers, Solid Carcinomas, Therapies, Therapy, Treatment, Tumor Vascularization, University of Leicester. This article was prepared by Cancer Weekly editors from staff and other reports. Copyright 2009, Cancer Weekly via NewsRx.com.
|
